Optically active dihydropyridine derivative

Abstract

The optically active compound (R)-2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-(1-diphenylmethylazetidin-3-yl) ester 5-isopropyl ester or a pharmacologically acceptable salt thereof, and a method using the compound or its salt to treat circulatory diseases.

1 . A compound designated (R)-2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-(1-diphenylmethylazetidin-3-yl) ester 5-isopropyl ester or a pharmacologically acceptable salt thereof.  
   
   
       2 . A compound designated (R)-2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-(1-diphenylmethylazetidin-3-yl) ester 5-isopropyl ester.  
   
   
       3 . A pharmacologically acceptable salt of the compound of  claim 1 .  
   
   
       4 . The salt of  claim 3 , wherein the salt is a salt of an acid selected from the group consisting of hydrofluorides, hydrochlorides, hydrobromides and hydroiodides.  
   
   
       5 . The salt of  claim 3 , wherein the salt is a nitrate, perchlorate, sulfate, phosphate, sulfonate or carboxylate.  
   
   
       6 . The salt of  claim 3 , wherein the salt is a salt of an amino acid.  
   
   
       7 . A composition for treating circulatory diseases selected from the group consisting of hypertension, angina pectoris, arteriosclerosis and kidney disorders comprising an effective amount of the compound of  claim 1  or a pharmacologically acceptable salt thereof combined with a pharmacologically acceptable additive.  
   
   
       8 . A method for treating circulatory diseases selected from the group consisting of hypertension, angina pectoris, arteriosclerosis and kidney disorders comprising administering an effective amount of the compound of  claim 1  or a pharmacologically acceptable salt thereof to a warm-blooded mammal.  
   
   
       9 . The method of  claim 8 , wherein the mammal is an adult human.  
   
   
       10 . The method of  claim 9 , wherein 0.002 mg/kg to 10 mg/kg are administered orally once to six times a day.  
   
   
       11 . The method of  claim 9 , wherein 0.0002 mg/kg to 0.001 mg/kg are administered parenterally once to six times a day.  
   
   
       12 . The method of  claim 8 , wherein 0.002 mg/kg to 10 mg/kg are administered orally once to six times a day.  
   
   
       13 . The method of  claim 8 , wherein 0.0002 mg/kg to 0.001 mg/kg are administered once to six times a day, parenterally.  
   
   
       14 . A method to delay the onset of circulatory diseases selected from the group consisting of hypertension, angina pectoris, arteriosclerosis and kidney disorders comprising administering an effective amount of the compound of  claim 1  or a pharmacologically acceptable salt thereof to a warm-blooded mammal.  
   
   
       15 . The method of  claim 14 , wherein the mammal is an adult human.  
   
   
       16 . The method of  claim 15 , wherein 0.002 mg/kg to 10 mg/kg are administered orally once to six times a day.  
   
   
       17 . The method of  claim 15 , wherein 0.0002 mg/kg to 0.001 mg/kg are administered parenterally once to six times a day.  
   
   
       18 . The method of  claim 14 , wherein 0.002 mg/kg to 10 mg/kg are administered orally once to six times a day.  
   
   
       19 . The method of  claim 14 , wherein 0.0002 mg/kg to 0.001 mg/kg are administered once to six times a day, parenterally.